新股上市:丹麦生物制药公司Zealand Pharma A/S(ZEAL)

  • A+

Zealand Pharma A/S(NASDAQ:ZEAL)创立于1997年4月1日,前称Peptide Probe Technologies ApS,于1998年12月2日更名为Zealand Pharmaceuticals ApS,并于同月22日重组为一家公共有限责任公司,同时更名为Zealand Pharmaceuticals A/S,2002年5月7日,公司更名为现用名Zealand Pharma A/S,总部位于丹麦哥本哈根,全职雇员118人(3/31/2017),是一家生物制药公司,专注于创新的基于肽的药物的发现,设计和开发。

新股上市:丹麦生物制药公司Zealand Pharma A/S(ZEAL)

Zealand Pharma A/S(ZEAL)美股百科:

Zealand Pharma A/S的产品组合包括两种经认可的2型糖尿病治疗产品:

  1. 利昔沙肽(lixisenatide)——已被美国食品和药物管理局(FDA)批准,在美国市场上以品牌名称Adlyxin销售;并已获得欧洲药品管理局(EMA),以及美国以外的其他监管机构批准,以品牌名称Lyxumia销售。该产品2016年全球销量3730万美元。2017年前6个月,该产品销售额为1580万美金。
  2. 由lixisenatide与Lantus组成的药物组合——(Lantus是由Sanofi SA开发的甘精胰岛素的品牌名称)已被FDA批准,并以品牌名称Soliqua100 / 33在美国市场销售;并已被EMA批准,并以品牌名称Suliqua(苏利柯)在荷兰推出。预计2017下半年,Suliqua将陆续在欧洲其他国家推出。该产品2017上半年销售额为1040万美金。

Adlyxin® / Lyxumia®和Soliqua™ 100/33 / Suliqua,均由赛诺菲根据许可协议进行销售,Zealand Pharma授予赛诺菲对这些产品的商业化权利。

Zealand Pharma A/S(ZEAL)美股投资:

Zealand Pharma A/S(NASDAQ:ZEAL)于8/9/2017 IPO登陆纳斯达克全球精选市场,发行价$17.87美元,发行437.5万股,募资$78,181,250.00美元,股票代码:ZEAL。

  • 参考资料:
行情 =点击直达行情= 财报 =财报日及评级=
百科 ==美股百科== 机构 ==前10大股东==
官网 ==公司官网== 分析 ==财报及其他==
美股之家
  • 版权声明:本站原创文章,于八月 13, 201706:52:31,由 美股百科 发表,共 949 字。
  • 转载必须获得授权,请联系站长。

发表评论

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :???: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen:

目前评论:1   其中:访客  1   博主  0

    • avatar 美股之家 8

      About us

      Zealand Pharma A/S was founded in 1997 and is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. We intend to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other specialty disease areas with significant unmet medical needs.. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim.

      Our pipeline focusing on gastrointestinal, metabolic and other specialty diseases where we believe that the present standard of care is inadequate and where we have the resources to advance our peptide-based product candidates into the later stages of clinical development, including registration and, potentially, commercialization, while opportunistically considering partnership relationships that may arise.

      In addition, we are looking to focus our efforts on drug candidates that may qualify for orphan / rare disease status. Our research and development, or R&D, organization is structured to enable dynamic collaboration across various functions and project teams at each stage of discovery and development, allowing us to advance promising opportunities quickly and take advantage of our extensive knowledge of peptide design and product development.

      We have a track record of successfully inventing and developing novel peptide-based product candidates. This success is based on our deep understanding of peptide chemistry and extensive experience in improving the therapeutic characteristics of naturally-occurring peptides by modifying and optimizing their structures. The modifications we make are designed to improve upon naturally occurring peptides so that their therapeutic benefit, duration of action, stability and/or convenience of use favorably compare to other treatment options.

      Marketed products —— Adlyxin® / Lyxumia®

      Our portfolio of approved medicines includes lixisenatide, which we have licensed to Sanofi. Lixisenatide is our first out-licensed product approved by both the FDA and the EMA. It is marketed by Sanofi for the treatment of adults with type 2 diabetes in 45 countries outside the United States under the brand name Lyxumia®, and in the United States under the brand name Adlyxin®.

      Type 2 diabetes is a disorder that is characterized by high blood glucose, or sugar, and caused by the insufficient production of insulin and/or an inability of the body to adequately respond to insulin. Adlyxin® / Lyxumia® is a once-daily glucagon-like peptide-1, or GLP-1, analog that we invented. It is a synthetic form of the naturally occurring GLP-1 found in the intestines that acts as a signaling hormone, stimulating the pancreas to produce more insulin.

      Clinical trials

      Adlyxin® / Lyxumia® has been observed in clinical trials to lower levels of hemoglobin A1c, or HbA1c (a measure of the three-month average blood glucose level), with a particular effect on meal-related, or prandial, glucose. Lyxumia, was first approved in Europe in 2013 to improve glycemic, or glucose level, control in adult type 2 diabetes patients and has now been approved in 61 countries.

      Adlyxin® received FDA approval on July 27, 2016 and Sanofi is currently marketing Adlyxin® in the United States. Lyxumia® is approved outside the United States for use in combination with oral glucose-lowering diabetes medicines or basal, or long-acting, insulin when these treatments, together with diet and exercise, do not provide adequate glycemic control. Adlyxin® is approved in the United States as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

      Soliqua™ 100/33 / Suliqua

      Sanofi has also developed a combination of lixisenatide and Lantus which received approval from the FDA on November 21, 2016 and from the EMA on January 17, 2017. One of these combinations is currently marketed in the United States by Sanofi under the brand name Soliqua100/33 and the other and the other has been launched in the Netherlands and the United Kingdom under the brand name Suliqua. Suliqua is expected to be launched in certain other individual European countries beginning in the second half of 2017. Soliqua100/33 is marketed in a single pre-filled SoloSTAR pen for once-daily dosing covering 15 to 60 units of insulin glargine 100 units/mL and 5 to 20 mcg of lixisenatide. Suliqua is marketed in two pre-filled SoloSTAR pens providing different dosing options: a 10-40 SoloSTAR pre-filled pen will deliver 10 to 40 dose steps of insulin glargine 100 units/mL in combination with 5 to 20 mcg of lixisenatide, whereas a 30-60 SoloSTAR pre-filled pen will deliver 30 to 60 units of insulin glargine 100 units/mL in combination with 10 to 20 micrograms of lixisenatide. SoloSTAR is the most frequently used disposable insulin injection pen platform in the world.

      Soliqua™ 100/33 / Suliqua is one of the first combinations of a GLP-1 analog and basal insulin to treat type 2 diabetes to be approved for marketing and launched for sale in the United States and is one of only two products (the other being Novo Nordisk’s Xultophy, which is a combination of its GLP-1 analog Victoza and basal insulin Tresiba) in this new product class. Soliqua100/33 is approved in the United States as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) or lixisenatide alone. Suliqua is authorized in Europe for use in combination with metformin to improve glycemic control when this has not been provided by metformin alone or metformin combined with another oral glucose lowering medicinal product or with basal insulin.

      Clinical trials

      Soliqua™ 100/33 / Suliqua has been observed in clinical trials to result in benefits, as compared to treatments with either basal insulin or a GLP-1 analog alone, pointing towards what we believe to be a potentially significant commercial opportunity.

      Product pipeline

      Our internal pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon, formulated for use in a single-dose, ready-to-use disposable injection pen, which is being developed as a rescue treatment for severe hypoglycemia or ‘‘insulin shock’’; and dasiglucagon, formulated for use in multiple-dose administrations, which is being developed for use in new treatment concepts for insulin-dependent diabetes patients, such as a dual-hormone artificial pancreas system for improved hypoglycemia control and better diabetes management and a single hormone pump for the treatment of congenital hyperinsulinism, or CHI.
      Licensed product candidates

      We have also out licensed product candidates to Boehringer Ingelheim International GmbH, or BI. We have out licensed two peptide programs to BI that have been advanced into preclinical development: a once-weekly novel dual glucagon/GLP-1 receptor agonist product candidate for the treatment of diabetes and/or obesity and a novel long-acting amylin analog for the treatment of obesity and diabetes. The lead product candidates for each collaboration were selected in February 2016 and October 2015, respectively.

      In the second half of 2016, BI confirmed its intention to bring both product candidates into Phase 1 clinical testing in the third quarter of 2017.